Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2009 1
2015 1
2016 1
2017 1
2018 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Esomeprazole response"
Page 1
Patient-centered Outcomes with Concomitant Use of Proton Pump Inhibitors and Other Drugs.
Shamliyan TA, Middleton M, Borst C. Shamliyan TA, et al. Clin Ther. 2017 Feb;39(2):404-427.e36. doi: 10.1016/j.clinthera.2017.01.011. Epub 2017 Feb 9. Clin Ther. 2017. PMID: 28189362 Review.
Concomitant PPIs reduce drug-induced gastrointestinal bleeding and are associated with greater docetaxel and cisplatin response rates in patients with metastatic breast cancer. For demonstrated statistically significant relative risks and benefits from concomitant PPIs, th …
Concomitant PPIs reduce drug-induced gastrointestinal bleeding and are associated with greater docetaxel and cisplatin response rates …
Efficacy of Pharmacologic Therapy for Eosinophilic Esophagitis: A Systematic Review and Network Meta-Analysis.
Tomizawa Y, Melek J, Komaki Y, Kavitt RT, Sakuraba A. Tomizawa Y, et al. J Clin Gastroenterol. 2018 Aug;52(7):596-606. doi: 10.1097/MCG.0000000000000878. J Clin Gastroenterol. 2018. PMID: 28787360
Six pharmacologic treatments (budesonide suspension and viscous, fluticasone, prednisone, esomeprazole, and mepolizumab) and placebo were included in our analysis. ...Subgroup analysis demonstrated prednisone, budesonide suspension, and esomeprazole were the most ef …
Six pharmacologic treatments (budesonide suspension and viscous, fluticasone, prednisone, esomeprazole, and mepolizumab) and placebo …
Efficacy of Proton Pump Inhibitor Drugs for Inducing Clinical and Histologic Remission in Patients With Symptomatic Esophageal Eosinophilia: A Systematic Review and Meta-Analysis.
Lucendo AJ, Arias Á, Molina-Infante J. Lucendo AJ, et al. Clin Gastroenterol Hepatol. 2016 Jan;14(1):13-22.e1. doi: 10.1016/j.cgh.2015.07.041. Epub 2015 Aug 3. Clin Gastroenterol Hepatol. 2016. PMID: 26247167 Review.
Secondary outcomes were the influence on the response to PPIs of age group, study design/quality, PPI type, doses and interval dosing, and pH monitoring results. ...A significant publication bias in favor of studies reporting histologic responses to PPIs was observe …
Secondary outcomes were the influence on the response to PPIs of age group, study design/quality, PPI type, doses and interval dosing …
Systematic review: standard- and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis -- a mixed treatment comparison of randomized controlled trials.
Edwards SJ, Lind T, Lundell L, DAS R. Edwards SJ, et al. Aliment Pharmacol Ther. 2009 Sep 15;30(6):547-56. doi: 10.1111/j.1365-2036.2009.04077.x. Epub 2009 Jun 25. Aliment Pharmacol Ther. 2009. PMID: 19558609 Free article. Review.
AIM: To compare the effectiveness of licensed doses of PPIs for healing severe erosive oesophagitis (i.e. esomeprazole 40 mg, lansoprazole 30 mg, omeprazole 20 mg and 40 mg, pantoprazole 40 mg and rabeprazole 20 mg). ...No other PPI investigated had significantly higher he …
AIM: To compare the effectiveness of licensed doses of PPIs for healing severe erosive oesophagitis (i.e. esomeprazole 40 mg, lansopr …
Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis.
Edwards SJ, Lind T, Lundell L. Edwards SJ, et al. Aliment Pharmacol Ther. 2001 Nov;15(11):1729-36. doi: 10.1046/j.1365-2036.2001.01128.x. Aliment Pharmacol Ther. 2001. PMID: 11683686 Free article.
BACKGROUND: Esomeprazole is a new proton pump inhibitor, which has been compared to omeprazole for the treatment of reflux oesophagitis in clinical trials. AIM: To compare the effectiveness of esomeprazole with the recommended dose of proton pump inhibitors in the h …
BACKGROUND: Esomeprazole is a new proton pump inhibitor, which has been compared to omeprazole for the treatment of reflux oesophagit …